Expression of human butyrylcholinesterase with an engineered glycosylation profile resembling the plasma-derived orthologue

Jeannine D. Schneider, Alexandra Castilho, Laura Neumann, Friedrich Altmann, Andreas Loos, Latha Kannan, Tsafrir Leket-Mor, Herta Steinkellner

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Human butyrylcholinesterase (BChE) is considered a candidate bioscavenger of nerve agents for use in pre- and post-exposure treatment. However, the presence and functional necessity of complex N-glycans (i.e. sialylated structures) is a challenging issue in respect to its recombinant expression. Here we transiently co-expressed BChE cDNA in the model plant Nicotiana benthamiana with vectors carrying the genes necessary for in planta protein sialylation. Site-specific sugar profiling of secreted recombinant BChE (rBChE) collected from the intercellular fluid revealed the presence of mono- and di-sialylated N-glycans, which largely resembles to the plasma-derived orthologue. Attempts to increase that sialylation content of rBChE by the over-expression of an additional glycosylation enzyme that generates branched N-glycans (i.e. β1,4-N-acetylglucosaminyl-transferase IV), allowed the production of rBChE decorated with tri-sialylated structures (up to 70%). Sialylated and non-sialylated plant-derived rBChE exhibited functional in vitro activity comparable to that of its commercially available equine-derived counterpart. These results demonstrate the ability of plants to generate valuable proteins with designed sialylated glycosylation profiles optimized for therapeutic efficacy. Moreover, the efficient synthesis of carbohydrates present only in minute amounts on the native protein (tri-sialylated N-glycans) facilitates the generation of a product with superior efficacies and/or new therapeutic functions.

Original languageEnglish (US)
Pages (from-to)501-510
Number of pages10
JournalBiotechnology Journal
Volume9
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Butyrylcholinesterase
Glycosylation
Polysaccharides
Proteins
Extracellular Fluid
Transferases
Horses
Tobacco
Complementary DNA
Carbohydrates
Enzymes
Therapeutics
Genes

Keywords

  • Butyrylcholinesterase
  • Glycoengineering
  • Plants
  • Recombinant biopharmaceuticals
  • Sialic acid

ASJC Scopus subject areas

  • Applied Microbiology and Biotechnology
  • Molecular Medicine

Cite this

Schneider, J. D., Castilho, A., Neumann, L., Altmann, F., Loos, A., Kannan, L., ... Steinkellner, H. (2014). Expression of human butyrylcholinesterase with an engineered glycosylation profile resembling the plasma-derived orthologue. Biotechnology Journal, 9(4), 501-510. https://doi.org/10.1002/biot.201300229

Expression of human butyrylcholinesterase with an engineered glycosylation profile resembling the plasma-derived orthologue. / Schneider, Jeannine D.; Castilho, Alexandra; Neumann, Laura; Altmann, Friedrich; Loos, Andreas; Kannan, Latha; Leket-Mor, Tsafrir; Steinkellner, Herta.

In: Biotechnology Journal, Vol. 9, No. 4, 2014, p. 501-510.

Research output: Contribution to journalArticle

Schneider, Jeannine D. ; Castilho, Alexandra ; Neumann, Laura ; Altmann, Friedrich ; Loos, Andreas ; Kannan, Latha ; Leket-Mor, Tsafrir ; Steinkellner, Herta. / Expression of human butyrylcholinesterase with an engineered glycosylation profile resembling the plasma-derived orthologue. In: Biotechnology Journal. 2014 ; Vol. 9, No. 4. pp. 501-510.
@article{1a37ecfc87844534a8ed8b59db3cd8e3,
title = "Expression of human butyrylcholinesterase with an engineered glycosylation profile resembling the plasma-derived orthologue",
abstract = "Human butyrylcholinesterase (BChE) is considered a candidate bioscavenger of nerve agents for use in pre- and post-exposure treatment. However, the presence and functional necessity of complex N-glycans (i.e. sialylated structures) is a challenging issue in respect to its recombinant expression. Here we transiently co-expressed BChE cDNA in the model plant Nicotiana benthamiana with vectors carrying the genes necessary for in planta protein sialylation. Site-specific sugar profiling of secreted recombinant BChE (rBChE) collected from the intercellular fluid revealed the presence of mono- and di-sialylated N-glycans, which largely resembles to the plasma-derived orthologue. Attempts to increase that sialylation content of rBChE by the over-expression of an additional glycosylation enzyme that generates branched N-glycans (i.e. β1,4-N-acetylglucosaminyl-transferase IV), allowed the production of rBChE decorated with tri-sialylated structures (up to 70{\%}). Sialylated and non-sialylated plant-derived rBChE exhibited functional in vitro activity comparable to that of its commercially available equine-derived counterpart. These results demonstrate the ability of plants to generate valuable proteins with designed sialylated glycosylation profiles optimized for therapeutic efficacy. Moreover, the efficient synthesis of carbohydrates present only in minute amounts on the native protein (tri-sialylated N-glycans) facilitates the generation of a product with superior efficacies and/or new therapeutic functions.",
keywords = "Butyrylcholinesterase, Glycoengineering, Plants, Recombinant biopharmaceuticals, Sialic acid",
author = "Schneider, {Jeannine D.} and Alexandra Castilho and Laura Neumann and Friedrich Altmann and Andreas Loos and Latha Kannan and Tsafrir Leket-Mor and Herta Steinkellner",
year = "2014",
doi = "10.1002/biot.201300229",
language = "English (US)",
volume = "9",
pages = "501--510",
journal = "Biotechnology Journal",
issn = "1860-6768",
publisher = "Wiley-VCH Verlag",
number = "4",

}

TY - JOUR

T1 - Expression of human butyrylcholinesterase with an engineered glycosylation profile resembling the plasma-derived orthologue

AU - Schneider, Jeannine D.

AU - Castilho, Alexandra

AU - Neumann, Laura

AU - Altmann, Friedrich

AU - Loos, Andreas

AU - Kannan, Latha

AU - Leket-Mor, Tsafrir

AU - Steinkellner, Herta

PY - 2014

Y1 - 2014

N2 - Human butyrylcholinesterase (BChE) is considered a candidate bioscavenger of nerve agents for use in pre- and post-exposure treatment. However, the presence and functional necessity of complex N-glycans (i.e. sialylated structures) is a challenging issue in respect to its recombinant expression. Here we transiently co-expressed BChE cDNA in the model plant Nicotiana benthamiana with vectors carrying the genes necessary for in planta protein sialylation. Site-specific sugar profiling of secreted recombinant BChE (rBChE) collected from the intercellular fluid revealed the presence of mono- and di-sialylated N-glycans, which largely resembles to the plasma-derived orthologue. Attempts to increase that sialylation content of rBChE by the over-expression of an additional glycosylation enzyme that generates branched N-glycans (i.e. β1,4-N-acetylglucosaminyl-transferase IV), allowed the production of rBChE decorated with tri-sialylated structures (up to 70%). Sialylated and non-sialylated plant-derived rBChE exhibited functional in vitro activity comparable to that of its commercially available equine-derived counterpart. These results demonstrate the ability of plants to generate valuable proteins with designed sialylated glycosylation profiles optimized for therapeutic efficacy. Moreover, the efficient synthesis of carbohydrates present only in minute amounts on the native protein (tri-sialylated N-glycans) facilitates the generation of a product with superior efficacies and/or new therapeutic functions.

AB - Human butyrylcholinesterase (BChE) is considered a candidate bioscavenger of nerve agents for use in pre- and post-exposure treatment. However, the presence and functional necessity of complex N-glycans (i.e. sialylated structures) is a challenging issue in respect to its recombinant expression. Here we transiently co-expressed BChE cDNA in the model plant Nicotiana benthamiana with vectors carrying the genes necessary for in planta protein sialylation. Site-specific sugar profiling of secreted recombinant BChE (rBChE) collected from the intercellular fluid revealed the presence of mono- and di-sialylated N-glycans, which largely resembles to the plasma-derived orthologue. Attempts to increase that sialylation content of rBChE by the over-expression of an additional glycosylation enzyme that generates branched N-glycans (i.e. β1,4-N-acetylglucosaminyl-transferase IV), allowed the production of rBChE decorated with tri-sialylated structures (up to 70%). Sialylated and non-sialylated plant-derived rBChE exhibited functional in vitro activity comparable to that of its commercially available equine-derived counterpart. These results demonstrate the ability of plants to generate valuable proteins with designed sialylated glycosylation profiles optimized for therapeutic efficacy. Moreover, the efficient synthesis of carbohydrates present only in minute amounts on the native protein (tri-sialylated N-glycans) facilitates the generation of a product with superior efficacies and/or new therapeutic functions.

KW - Butyrylcholinesterase

KW - Glycoengineering

KW - Plants

KW - Recombinant biopharmaceuticals

KW - Sialic acid

UR - http://www.scopus.com/inward/record.url?scp=84897094860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897094860&partnerID=8YFLogxK

U2 - 10.1002/biot.201300229

DO - 10.1002/biot.201300229

M3 - Article

C2 - 24130173

AN - SCOPUS:84897094860

VL - 9

SP - 501

EP - 510

JO - Biotechnology Journal

JF - Biotechnology Journal

SN - 1860-6768

IS - 4

ER -